Our Mission

Zynerba’s mission is to develop next-generation transdermally-delivered cannabinoid therapeutics to help address significant unmet medical needs and improve the lives of patients with rare and near-rare neuropsychiatric conditions such as Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).

In order to achieve this for our patients and stakeholders, we have assembled an experienced and dedicated team at Zynerba; together, we have a proven development and commercialization track record and extensive experience in transdermal delivery, rare and orphan diseases, neurology, and psychiatry.